PDCD1 and cancer: Furthermore, NBTXR3+RT supported an immunogenic cell death-mediated effect in preclinical trials (e.g., NCT03589339), and immunocompetent cell infiltration in some advanced cancers treated with an anti-PD-1 therapy.